OxSyBio, an Oxford University biotech spinout company developing 3D printer technology capable of printing biological materials with a diverse range of therapeutic purposes, has secured £10m in Series A financing from Woodford Investment Management alongside new and existing backers.
OxSyBio has a unique 3D printing platform which enables it to assemble the building blocks of life. The synthetic biology company’s ultimate ambition is to fabricate therapeutic tissues for patients using living cells or non-living ‘artificial’ cells, or hybrid materials. These tissues have the potential to revolutionise the growing field of regenerative medicine, allowing for the literal printing of new tissues that can be used to repair or replace parts of the body damaged through disease or injury.